Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 469Neoplasms 327Colorectal Neoplasms 236Carcinoma, Non-Small-Cell Lung 233Lung Neoplasms 200Prostatic Neoplasms 179Carcinoma, Hepatocellular 173Stomach Neoplasms 138Pancreatic Neoplasms 126Leukemia, Myeloid, Acute 114Uterine Cervical Neoplasms 110Rectal Neoplasms 105Multiple Myeloma 93Recurrence 88Squamous Cell Carcinoma of Head and Neck 84Head and Neck Neoplasms 78Neoplasm Metastasis 76Ovarian Neoplasms 75Brain Neoplasms 69Colonic Neoplasms 68Glioblastoma 66Esophageal Neoplasms 66Triple Negative Breast Neoplasms 65Endometrial Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Small Cell Lung Carcinoma 54Disease 54Motor Activity 53Hematologic Neoplasms 53Glioma 46

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × HER2 Overexpression × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡